Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
In athletes, Bifidobacterium longum BB536 did not significantly improve gastrointestinal symptoms overall, though some benefits were seen in specific subgroups.
Yes, early evidence suggests transcutaneous auricular vagus nerve stimulation may improve symptoms in some gastrointestinal disorders, especially constipation-predominant IBS…
SGLT2 inhibitors may lower all-cause mortality in transthyretin cardiomyopathy, but evidence is mixed; one study shows benefit, another shows no mortality reduction when added to…
Yes, furosemide plus hypertonic saline is linked to lower increases in biomarkers like NT-proBNP, IL-6, and sST2 after a saline load in ADHF patients, though baseline reductions…
Yes, natriuresis-guided protocols increase weight loss in acute decompensated heart failure, with a meta-analysis showing about 0.45 kg more weight loss at 48 hours compared to…
Evidence is mixed: one meta-analysis found natriuresis-guided protocols shortened hospital stays by about 1 day, but another found no significant difference.
Yes, thermal ablation is a safe and effective treatment for small colorectal liver metastases, with low complication rates and survival outcomes comparable to surgery.
Immune checkpoint inhibitors (ICIs) show reduced effectiveness in patients with liver metastases, but combining them with local treatments or certain targeted therapies may…
Yes, chemoimmunotherapy improves survival in patients with liver metastases, with benefits similar to those without liver metastases, according to a large meta-analysis.
Yes, robotic surgery appears safe for treating colorectal cancer and liver metastases together in selected patients, with low conversion rates and no reported deaths in early…
Yes, sex differences exist: women with NVAF-related stroke tend to have worse short-term outcomes, but after adjusting for age and other factors, their long-term mortality risk…
Yes, left atrial appendage occlusion (LAAO) is associated with lower all-cause mortality compared to warfarin in patients with nonvalvular atrial fibrillation, based on network…
Yes, Xarelto (rivaroxaban) is FDA-approved for stroke prevention in nonvalvular atrial fibrillation, based on the ROCKET-AF trial showing it is noninferior to warfarin with a…
Yes, left atrial appendage closure (LAAC) causes significantly less non-procedural bleeding than NOACs in patients with nonvalvular atrial fibrillation, based on recent trials.
Yes, several genetic variants are linked to axial spondyloarthritis, most notably HLA-B27, and a 2026 meta-analysis identified additional risk and protective variants in genes…
Yes, long-term personalized exercise therapy appears potentially cost-effective for axial spondyloarthritis patients with severe functional limitations, though upfront costs are…
Yes, vunakizumab improves symptoms in active radiographic axial spondyloarthritis, with a 2026 trial showing significantly more patients achieving ASAS20 response at 16 weeks…
TNF inhibitors are linked to a small increased risk of non-melanoma skin cancer in axial spondyloarthritis, but overall cancer risk appears reassuring.
While some symptoms like brain fog or heart palpitations are more common after SARS-CoV-2 than other respiratory viruses, both types of infections can lead to serious…
Respiratory viral infections like SARS-CoV-2, influenza, and RSV are frequently monitored in the U.S., with varying impacts on patient outcomes such as hypoxemia and mortality.
During the COVID-19 pandemic, the detection of common respiratory viruses like influenza and RSV significantly decreased in pediatric settings.
Yes, research links microbiome changes (dysbiosis) to endometrial cancer risk through inflammation, immune effects, and estrogen metabolism.
Combined pelvic and para-aortic lymphadenectomy may improve survival in intermediate/high-risk endometrial cancer, but evidence is mixed and not definitive for all stages.
Current research focuses on PD-1/PD-L1 inhibitors, especially for MSI-H tumors, combination therapies, and understanding molecular subtypes to improve immunotherapy response in…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.